Alibaba’s TSMC-Built 5nm RISC-V Chip, XuanTie C950, Now Runs Qwen-3.8 27B Model Natively, Unlocking Massive Vertical Integration Tailwinds
Rohail Saleem / wccftech - Alibaba appears to be emulating NVIDIA's well-established vertical integration playbook by bringing day-zero support for its highly capable Qwen-3.8 27B AI model - one that can run on just 32GB of VRAM - to its bespoke RISC-V chip, called XuanTie C950. Al…
AI Summary: Harold P. Freeman, the architect of patient navigation and a tireless advocate for health equity in cancer care, has died at 93. Colleagues and organizations remember his decades of work reducing barriers to treatment, mentoring leaders, and reshaping how underserved patients access timely cancer services.
5 Surprising Signs of Aging
Jancee Dunn / nytimes - Hint: You may need to buy new shoes.
AI Summary: Phase III DESTINY‑Lung04 data show trastuzumab deruxtecan (Enhertu) significantly prolongs progression‑free survival as first‑line therapy for HER2‑mutant non‑small cell lung cancer. Investigators hail the efficacy signal, but oncologists caution that longer follow‑up is needed to determine whether the PFS benefit will translate into overall survival advantage.
Supercentenarians have an abundance of cancer-killing immune cells
medicalxpress - The human immune system has specialized cells called CD4 cytotoxic T lymphocytes (CD4 CTLs), which have been shown to kill tumor cells in some cancers. When a person gets sick, these cells multiply in a process called clonal expansion to help fight infect…
AI Summary: Analyses of people over 110 reveal an abundance of highly active cytotoxic immune cells capable of recognizing and eliminating cancerous cells, offering clues to extreme longevity. These hypervigilant immune profiles may explain low cancer rates among the very old and suggest immune‑based strategies that could one day mimic their natural defenses.
Charles Roberts Named the Next President and CEO of St. Jude Children’s Research Hospital
oncodaily - Charles Roberts, Current Cancer Center Director and Executive Vice-President and Next President and CEO of St. Jude Children’s Research Hospital, shared St. Jude Children’s Research Hospital’s post on LinkedIn, adding: […]
AI Summary: Charles Roberts was named president and CEO of St. Jude Children’s Research Hospital, stepping into leadership of a globally recognized pediatric cancer and research institution. He’ll oversee strategy, fundraising and clinical priorities as the center pursues ambitious research and care goals — and deal with the inevitable complexity of running a world-class nonprofit hospital.
ENZAMET: Enzalutamide Maintains Long-Term Survival Benefit in mHSPC
oncodaily - Treatment intensification with androgen receptor pathway inhibitors has become central to the management of metastatic hormone-sensitive prostate cancer (mHSPC). However, as patients remain on these therapies for years, longer follow-up […]
AI Summary: Long-term follow-up from ENZAMET shows enzalutamide continues to deliver a substantial overall survival benefit at eight years for patients with metastatic hormone-sensitive prostate cancer. The durable outcome cements enzalutamide’s role in combination androgen-deprivation strategies, giving patients and clinicians a proven option — not a cure, but progress that actually lasts.
Merck and Moderna’s Intismeran Autogene Plus Keytruda Meets Phase 3 RFS and DMFS Endpoints in Resected Melanoma
oncodaily - Merck and Moderna announced positive topline results from the Phase 3 INTerpath-001 trial, evaluating intismeran autogene (V940/mRNA-4157) plus Keytruda (pembrolizumab) as adjuvant treatment for patients with completely resected stage IIB-IV […]
AI Summary: Merck and Moderna announced that their mRNA-based melanoma vaccine, given with Keytruda, met key phase‑3 endpoints — reducing recurrence and distant metastasis after resection. The data suggest the vaccine can prime anti‑tumor immunity to prevent relapse, positioning it as a potential adjunct to standard checkpoint inhibition in high‑risk patients.
- Experts weigh in on personalized mRNA cancer vaccines (4)
- INTerpath-001: phase‑3 vaccine reduces melanoma recurrence (6)
- Market surge: Moderna's stock jumps after trial news (3)
- All Other Stories
Experts weigh in on personalized mRNA cancer vaccines
INTerpath-001: phase‑3 vaccine reduces melanoma recurrence
Market surge: Moderna's stock jumps after trial news
All Other Stories
Belzutifan Plus Lenvatinib Improves Outcomes Over Cabozantinib in Patients with Advanced RCC Following Progression to PD1 or PD-L1 Inhibitors
esmo - Findings from the LITESPARK-011 study
AI Summary: A Phase 3 trial shows belzutifan combined with lenvatinib improves progression-free survival compared with cabozantinib in patients with advanced renal cell carcinoma who progressed on PD‑1/PD‑L1 inhibitors. The result offers a new sequenced treatment option and shifts the landscape for post–checkpoint inhibitor RCC management.
A simple blood test could detect multiple cancers and reveal where they started
sciencedaily - UCLA researchers have created a blood test that can scan DNA signals for multiple cancers, liver diseases, and signs of organ damage—and even indicate where trouble may be developing. Early results suggest the inexpensive approach could bring medicine clo…
AI Summary: Researchers report a blood test capable of detecting multiple cancer types and indicating their tissue of origin, offering a potential multi‑cancer early‑detection tool. While sensitivity, specificity and real‑world performance remain under evaluation, the approach could shift screening paradigms if validated across diverse populations and clinical settings.
Anas Younes: Decade-Long Persistence of CD19 CAR T Cells in B Cell Lymphomas
oncodaily - Anas Younes, Chief Medical Officer and Head of Haematology R&D at AstraZeneca, shared on LinkedIn: “While these findings demonstrate that CART19 cells can persist for more than 10 years in […]
AI Summary: Long-term follow-up shows CD19-directed CAR‑T cells can persist for a decade in patients with B‑cell lymphomas, associating with sustained remissions and reshaping expectations about durability, retreatment and long-term toxicity. These findings prompt rethinking of follow-up care and suggest cellular therapies may offer far longer benefits than anyone dared hope.
ASTRO updates guideline on radiation therapy for pancreatic cancer
medicalxpress - An updated clinical guideline from the American Society for Radiation Oncology (ASTRO) provides evidence-based recommendations on the use of radiation therapy to treat adult patients with pancreatic cancer.
AI Summary: ASTRO released updated 2026 guidance for radiation therapy in pancreatic cancer, refining target volumes, dose constraints, and technique recommendations. The update aims to standardize practice, improve safety for nearby organs at risk, and incorporate emerging evidence on hypofractionation and concurrent systemic therapies to better balance local control with toxicity.
Essentia Health names EVP from SSM Health
Kelly Gooch / beckershospitalreview - Jason Craig, most recently a regional vice president at St. Louis-based SSM Health, was named executive vice president of administration and operations at Duluth, Minn.-based Essentia Health, according to an Aug. 12 news release shared with Becker’s. Mr. …
AI Summary: Recent analyses and expert commentary propose that genomic newborn screening can identify children with cancer predisposition syndromes before tumors develop. Early detection would enable targeted surveillance and preventive measures, though ethical, logistical, and equity considerations remain central to implementing such programs at scale. Expect lively debate before universal adoption.
Wungki Park: First Map of Acquired Resistance to Daraxonrasib in Pancreatic Cancer
oncodaily - Wungki Park, Assistant Attending at Memorial Sloan Kettering Cancer Center, shared on X: “The first map of acquired resistance to the tri-complex RAS(ON) inhibitor daraxonrasib in PDAC published today in […]
AI Summary: Researchers have charted acquired resistance mechanisms to the RAS(ON) inhibitor daraxonrasib in pancreatic cancer, identifying pathways that suggest rational combination therapies. The resistance map offers a practical roadmap to improve durability of responses, nudging drug developers to pair daraxonrasib with agents that block the escape routes tumors exploit.
Air pollution-linked blood changes detected years before lung cancer diagnosis
medicalxpress - A new study, published Tuesday in Nature Communications, found measurable changes in people's blood associated with exposure to air pollution and the subsequent development of lung cancer. The findings provide promising clues that could help shape future …
AI Summary: New analyses link long‑term air pollution exposure to distinct blood metabolic and biomarker changes that appear years before lung cancer diagnosis, suggesting a window for earlier detection. The work identifies candidate pathways tying inhaled pollutants to carcinogenic processes and proposes blood‑based signals for future screening or risk stratification.
Lucy Davis Reveals Incurable Stage 4 Breast Cancer: Diagnosis, Bone Metastases, and What We Know
oncodaily - British actress Lucy Davis, best known for playing Dawn Tinsley in the original UK version of The Office, has revealed that she has been living with stage 4 breast cancer […]
AI Summary: Actor Lucy Davis disclosed a diagnosis of incurable stage‑4 breast cancer with bone metastases, using her platform to raise awareness about prognosis, screening and self‑examination. Her candid account underscores the reality of metastatic disease and encourages people to pay attention to subtle changes, not just lumps.
FDA Grants Accelerated Approval to Bristol Myers Squibb’s Zenbexus Plus Daratumumab and Hyaluronidase-fihj and Dexamethasone for Multiple Myeloma
oncodaily - The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Zenbexus (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd) for adults with multiple myeloma who have […]
AI Summary: Bristol Myers Squibb secured FDA approval of a first‑in‑class protein‑degrader regimen for multiple myeloma, cleared as a combination with daratumumab, hyaluronidase and dexamethasone. The nod marks a notable shift toward targeted degrader strategies in hematologic oncology and gives clinicians another option for patients with advanced disease.
FDA advisers to weigh cancer blood test
Ella Jeffries / beckershospitalreview - The FDA’s Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee will meet Sept. 23 to discuss and vote on Grail’s premarket approval application for its Galleri blood test, according to a notice published Aug. 10 in the Federal R…
AI Summary: FDA advisors are set to review a multi-cancer early-detection blood test, weighing evidence on accuracy, clinical utility, and how to handle follow-up diagnostics. Regulators must decide whether the test meets approval standards for broad screening, balancing potential earlier cancer detection against risks of false positives, overdiagnosis, and costly downstream workups.
AstraZeneca Holds Preliminary Talks with Bristol Myers Squibb on Potential $400 Billion Merger
oncodaily - A deal that could create the world’s fourth-largest drugmaker British pharmaceutical leader AstraZeneca has held confidential, preliminary discussions regarding a potential combination with US rival Bristol Myers Squibb(BMS). A completed […]
AI Summary: AstraZeneca entered preliminary, non-binding talks with Bristol Myers Squibb about a potential $400 billion merger, probing whether combining pipelines and scale could reshape oncology and other businesses. The discussions are early, sparking market speculation and likely regulatory scrutiny as executives weigh strategic synergies against integration complexity and antitrust risk.
Senate Moves to Keep Politics Out of Cancer Research Funding
oncodaily - On August 2, 2026, US senators introduced a bipartisan temporary spending bill aimed at keeping the federal government funded. The bill also included a provision that would pause earlier proposed […]
AI Summary: Lawmakers advanced a bipartisan measure designed to delay a controversial OMB grantmaking rule and protect peer‑reviewed cancer research funding from politicized oversight. Scientific groups welcomed the move as a pragmatic step to preserve grant integrity and ensure researchers can continue work without sudden administrative disruptions.
- Clinical leaders defend peer review, oppose politicized funding (3)
- Inclusion and funding roles shaping cancer clinical research (3)
- Senate stalls OMB rule to shield cancer grants (3)
Clinical leaders defend peer review, oppose politicized funding
Inclusion and funding roles shaping cancer clinical research
Senate stalls OMB rule to shield cancer grants
FDA Approved Pluvicto Plus ARPI for PSMA-Positive mAPMN/S Prostate Cancer
oncodaily - On July 31, 2026, the US Food and Drug Administration approved lutetium Lu 177 vipivotide tetraxetan, marketed as Pluvicto, in combination with androgen receptor pathway inhibitor (ARPI) therapy for adults […]
AI Summary: The FDA has approved an expanded use for a lutetium‑177 radiopharmaceutical (Pluvicto), broadening access for PSMA‑positive metastatic prostate cancer patients and potentially speeding the adoption of targeted radionuclide therapy. Clinicians note the approval could shift treatment sequencing and patient pathways, with implementation details and eligibility criteria guiding real‑world impact.
- Access, dose optimization and real-world data for Lu-177 (4)
- FDA expands Pluvicto approval; industry reaction (3)
- PSMAddition trial: earlier Lu-177 delays metastatic progression (5)
Access, dose optimization and real-world data for Lu-177
FDA expands Pluvicto approval; industry reaction
PSMAddition trial: earlier Lu-177 delays metastatic progression
Mel Mann Highlights First Patient Enrollment in AACR-ADOPT-GEA Trial
oncodaily - Mel Mann, World’s Longest Living Gleevec (Imatinib) / TKI Survivor, 31-year terminal Chronic Myeloid Leukemia (CML) Survivor, Clinical Trial Pioneer, and Patient Advocate, shared American Association for Cancer Research (AACR) […]
AI Summary: The AACR‑affiliated ADOPT‑GEA phase II trial for locally advanced gastroesophageal cancer has reported its first patient enrollment, marking a key milestone in the study's launch. The enrollment signals trial readiness and opens recruitment momentum to evaluate investigational approaches for a challenging cancer subtype, advancing potential new treatment options toward evidence‑based use.